WIM
LGND icon

WealthPlan Investment Management’s Ligand Pharmaceuticals LGND Stock Holding History

WealthPlan Investment Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-100
Closed -$7.36K – 425
2023
Q1 		$7.36K Buy
+100
New +$7.11K ﹤0.01% 343

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

WealthPlan Investment Management's LGND Position: Q2 2023 in Review

WealthPlan Investment Management sold out of Ligand Pharmaceuticals (LGND) in Q2 2023, closing a stake of 100 shares — an estimated $7.36K sold.

WealthPlan Investment Management first reported a position in LGND in Q1 2023 and held it in 1 quarter. The position peaked at $7.36K in Q1 2023. 204 funds tracked by Wall St. Rank hold LGND as of Q2 2023.

  • WealthPlan Investment Management reported no remaining Ligand Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • WealthPlan Investment Management sold 100 Ligand Pharmaceuticals shares in Q2 2023, an estimated $7.36K.
  • WealthPlan Investment Management first reported a position in Ligand Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • WealthPlan Investment Management's Ligand Pharmaceuticals position peaked at $7.36K in Q1 2023.
  • 204 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2023.

Based on WealthPlan Investment Management's 13F filing for Q2 2023, filed 25 Jul 2023.